A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Verastem, Inc.
Verastem, Inc.
Servier
Bristol-Myers Squibb
AstraZeneca
Phanes Therapeutics
Vanderbilt-Ingram Cancer Center
Cantargia AB
EMD Serono
Hoosier Cancer Research Network
Incyte Corporation
University of Texas Southwestern Medical Center
Bristol-Myers Squibb
Vanderbilt-Ingram Cancer Center